# Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

> **NCT03120676** · PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03120676
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-14
- **Primary completion:** 2018-11-12
- **Final completion:** 2018-11-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2019-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03120676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03120676, "Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03120676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*